Dr. Alfredo Quijano Rubio, PhDChief Scientific Officer at Monod BioSpeaker
Profile
Alfredo Quijano Rubio is a scientist and entrepreneur specializing in computational protein design. He is the co-founder and Chief Scientific Officer (CSO) of Monod Bio, a company pioneering the design of novel diagnostics and research reagents using AI-powered computational protein design. He obtained a Ph.D. in Bioengineering at the University of Washington under the mentorship of Professor David Baker, Nobel Prize in Chemistry in 2024. His research on designing conditionally-active proteins for immunotherapy and biosensors resulted in high-impact scientific publications, patents, and the creation of two companies: Neoleukin Therapeutics and Monod Bio. Alfredo has been recognized by Business Insider and by the Puget Sound Business Journal as one of the young leaders revolutionizing the healthtech sector.
Agenda Sessions
NovoBody Platform: Next-generation Antibodies Engineered by Computational Protein Design
, 08:50View Session